Notice of Proposed Sale · 144
Vaxcyte, Inc.
PCVXNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- Vaxcyte, Inc.
- Issuer CIK
- 0001649094
- SEC file number
- 001-39323
- Phone
- 650-837-0111
- Person for whose account securities are to be sold
- Wassil Jim
- Relationships to issuer
- Officer
- Street
- 825 INDUSTRIAL ROAD, STE. 300
- City
- SAN CARLOS
- State / country code
- CA
- Postal code
- 94070
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 2,250 | 127,642.50 | 148,805,278 | 10/01/2026 | NASDAQ | UBS Financial Services, Inc. |
Broker / market maker — proposed row 1, entry 1
- Name
- UBS Financial Services, Inc.
- Street
- 11 Madison Ave
- Street (continued)
- 4th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10010
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 10/01/2026 | Exercise of stock option | Issuer | 2,250 | N | 10/01/2026 | Cash |
Sales reported in the preceding three months
| Seller | Security | Sale date | Amount sold | Gross proceeds |
|---|---|---|---|---|
| James Wassil | Common | 07/01/2026 | 2,250 | 126,735.98 |
| James Wassil | Common | 08/03/2026 | 2,250 | 121,194.45 |
| James Wassil | Common | 09/01/2026 | 3,477 | 212,352.66 |
| James Wassil | Common | 09/04/2026 | 1,381 | 84,462.51 |
| James Wassil | Common | 09/09/2026 | 1,334 | 79,400.61 |
Seller — prior-sale row 1, entry 1
- Name
- James Wassil
- Street
- 825 INDUSTRIAL ROAD, STE. 300
- City
- SAN CARLOS
- State / country code
- CA
- Postal code
- 94070
Seller — prior-sale row 2, entry 1
- Name
- James Wassil
- Street
- 825 INDUSTRIAL ROAD, STE. 300
- City
- SAN CARLOS
- State / country code
- CA
- Postal code
- 94070
Seller — prior-sale row 3, entry 1
- Name
- James Wassil
- Street
- 825 INDUSTRIAL ROAD, STE. 300
- City
- SAN CARLOS
- State / country code
- CA
- Postal code
- 94070
Seller — prior-sale row 4, entry 1
- Name
- James Wassil
- Street
- 825 INDUSTRIAL ROAD
- Street (continued)
- STE. 300
- City
- SAN CARLOS
- State / country code
- CA
- Postal code
- 94070
Seller — prior-sale row 5, entry 1
- Name
- James Wassil
- Street
- 825 INDUSTRIAL ROAD
- Street (continued)
- STE. 300
- City
- SAN CARLOS
- State / country code
- CA
- Postal code
- 94070
Prior-sale reporting
- Nothing to report for the preceding three months
- N
Notice signature
- Notice date
- 10/01/2026
- Signed
- /s/ UBS Financial Services Inc, as attorney-in-fact for James Wassil
- Plan adoption dates
- 12/09/2025
Company context
Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. VAX-31, a 31-valent PCV candidate advancing to a Phase 3 adult clinical program and currently being evaluated in a Phase 2 infant clinical program, is being developed for the prevention of IPD in adults and infants and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, the Company’s 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market and is currently being evaluated in a Phase 2 infant study. Both VAX-31 and VAX-24 are designed to improve upon the standard-of-care PCVs by covering the serotypes in circulation that are responsible for a significant portion of IPD and are associated with high case-fatality rates, antibiotic resistance and meningitis, while maintaining coverage of previously circulating strains that are currently contained through continued vaccination practice. Vaxcyte is re-engineering the way highly complex vaccines are made through modern synthetic techniques, including advanced chemistry and the XpressCF™ cell-free protein synthesis platform, exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company’s system for producing difficult-to-make proteins and antigens is intended to accelerate its ab